AUTHORS
Guangsheng He, Xiaoqing Liu2, Lei Fan, MD3
AFFILIATIONS
1 The First Affiliated Hospital with Nanjing Medical University/Jiangsu Province Hospital, and Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, Nanjing, China
2 The Second Hospital of Nanjing, Nanjing, China
3 The First Affiliated Hospital with Nanjing Medical University/Jiangsu Province Hospital, and Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, Nanjing, China
ABSTRACT
Background: Acquired pure red cell aplasia (aPRCA) is a rare bone marrow failure disorder. Cyclosporine A (CsA) is first-line therapy, but relapse frequently occurs during dose tapering. The optimal CsA tapering strategy remains undefined. This study compared rapid versus slow CsA tapering on relapse-free survival (RFS) in aPRCA.
Methods: Patients with aPRCA who had achieved complete or partial remission and maintained on CsA for ≥12 months were randomized 1:1 to rapid tapering (0.8 mg/kg/month) or slow tapering (0.3–0.7 mg/kg/month). Primary endpoints were relapse rate and RFS. Kaplan-Meier method and Cox regression were used for survival analysis. The study was performed in accordance with the Helsinki Declaration. All patients provided informed consent, with the clinical trial registration number ChiCTR2100043485.
Results: A total of 29 patients were included in the analysis (1 patient excluded due to insufficient follow-up), with 15 in the rapid tapering group and 14 in the slow tapering group. Baseline characteristics were well balanced: median age was 48 years (range, 19–71) in the rapid group versus 62.5 years (range, 39–75) in the slow group (P=0.070); male proportion was 46.7% vs 64.3% (P=0.462); etiological distribution (idiopathic PRCA 53.3% vs 21.4%, LGLL-associated 46.7% vs 64.3%) showed no significant difference (P=0.213). Baseline hemoglobin, reticulocyte percentage, leukocyte and platelet counts, and CsA maintenance dose (median 200 mg/d in both groups) were comparable between groups (all P>0.05).
With a median follow-up of 12.5 months, the relapse rate was 66.7% (10/15) in the rapid tapering group versus 57.1% (8/14) in the slow tapering group, without significant difference (P=0.710). Kaplan-Meier analysis showed that median RFS was 9.2 months in the rapid group and 24.0 months in the slow group. The 6-month RFS rates were 80.0% vs 92.3%, 12-month RFS rates were 40.9% vs 67.1%, and 24-month RFS rates were 30.7% vs 40.3%, respectively. Log-rank test suggested a trend toward better RFS in the slow tapering group, though the difference did not reach statistical significance (χ²=1.048, P=0.306).
Univariate Cox regression analysis revealed that rapid tapering (HR=11.09, 95% CI: 1.92–64.19, P=0.007), male sex (HR=4.67, 95% CI: 1.12–19.51, P=0.035), LGLL-associated PRCA (HR=4.23, 95% CI: 1.19–15.07, P=0.026), and higher baseline reticulocyte percentage (HR=2.02, 95% CI: 1.10–3.71, P=0.023) were independent risk factors for relapse.
Regarding safety, the adverse event rate was 13.3% (2/15) in the rapid group (elevated creatinine, hypertension) and 14.3% (2/14) in the slow group (elevated creatinine, liver dysfunction), with no significant difference (P=1.000). All events were grade 1–2, and no treatment-related deaths occurred.
Conclusions: This prospective randomized controlled study suggests that slow CsA tapering may prolong relapse-free survival in adult acquired PRCA, with acceptable safety. Rapid tapering, male sex, LGLL-associated PRCA, and higher baseline reticulocyte percentage are associated with increased relapse risk. Limited by sample size, these conclusions warrant further validation in larger cohorts.
DISCLOSURES
Guangsheng He: No relevant conflicts of interest to declare.